Need professional-grade analysis? Visit stockanalysis.com
$11.58B
47.89
1,522
N/A
Chengdu Easton Biopharmaceuticals Co Ltd (688513) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY65.71, down 1.72% from the previous close.
Over the past year, 688513 has traded between a low of CNY32.64 and a high of CNY79.60. The stock has gained 69.6% over this period. It is currently 17.4% below its 52-week high.
Chengdu Easton Biopharmaceuticals Co Ltd has a market capitalization of $11.58B, with a price-to-earnings ratio of 47.89.
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricaracetam and Lacosamide for neurological and psychiatric applications; and Empagliflozin for anti-diabetic applications. The company was founded in 2009 and is based in Chengdu, China.
Side-by-side comparison against top Healthcare peers.